A5016200536- Pharmacogenetics and Drug Metabolism
- Statistical Methods in Clinical Trials
- Computational Drug Discovery Methods
- Eicosanoids and Hypertension Pharmacology
- Biosimilars and Bioanalytical Methods
- Chemical Reactions and Isotopes
- Pharmacological Effects and Toxicity Studies
- Diet and metabolism studies
- Innovative Microfluidic and Catalytic Techniques Innovation
- Pharmaceutical studies and practices
- Schizophrenia research and treatment
University of Alberta
2019-2022
Women and Children’s Health Research Institute
2019-2021
ORCID
2021
Abstract Many antidepressants, atomoxetine, and several antipsychotics are metabolized by the cytochrome P450 enzymes CYP2D6 CYP2C19, guidelines for prescribers based on genetic variants exist. Although some laboratories offer such testing, there is no consensus regarding validated methodology clinical genotyping of CYP2C19 . The aim this paper was to cross-validate multiple technologies against each other, contribute feasibility implementation providing an enhanced range assay options,...
Abstract Background CYP2D6 and CYP2C19 are cytochrome P450 enzymes involved in the metabolism of many medications from multiple therapeutic classes. Associations between patterns variants (known as haplotypes) genes encoding them ( ) enzyme activities well described. The fact comprise 21% biomarkers drug labels. Despite this, genotyping is not common, partly attributable to its challenging nature having >100 haplotypes, including those with sequence an adjacent pseudogene, gene...
Abstract There are some data associating variants in the CYP2D6 and/or CYP2C19 genes with concentration-to-dose ratios, efficacy, and retention treatments. However, much of above arises from relatively small studies or large datasets limited genotyping methodologies. Our aim was to develop validate comprehensive accurate methodology for these two facilitate regenotyping hence generation more clinical associations. TaqMan copy number variant (CNV) assays were used identify samples a relevant...